These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25743849)

  • 1. TRAIL and Bortezomib: killing cancer with two stones.
    Qureshi MZ; Romero MA; Attar R; Javed Z; Farooqi AA
    Asian Pac J Cancer Prev; 2015; 16(4):1671-4. PubMed ID: 25743849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL mediated signaling in different cancers: cancer in the "Crosshairs".
    Farooqi AA; Naureen H; Yilmaz S; Sabitaliyevich UY; Zhailganov A; Rabandiyarov M; Ucak I; Karasholakova L; Attar R
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):1-8. PubMed ID: 34174975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Frontiers in Promoting TRAIL-Mediated Cell Death: Focus on Natural Sensitizers, miRNAs, and Nanotechnological Advancements.
    Farooqi AA; Gadaleta CD; Ranieri G; Fayyaz S; Marech I
    Cell Biochem Biophys; 2016 Mar; 74(1):3-10. PubMed ID: 26972296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin as a proteasome inhibitor. Is there any clinical evidence?
    Vriend J; Reiter RJ
    Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
    de Wilt LH; Kroon J; Jansen G; de Jong S; Peters GJ; Kruyt FA
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):363-72. PubMed ID: 22944363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
    Brooks AD; Ramirez T; Toh U; Onksen J; Elliott PJ; Murphy WJ; Sayers TJ
    Ann N Y Acad Sci; 2005 Nov; 1059():160-7. PubMed ID: 16382051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dealing naturally with stumbling blocks on highways and byways of TRAIL induced signaling.
    Rana A; Attar R; Qureshi MZ; Gasparri ML; Donato VD; Ali GM; Farooqi AA
    Asian Pac J Cancer Prev; 2014; 15(19):8041-6. PubMed ID: 25338981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoring TRAIL mediated signaling in ovarian cancer cells.
    Farooqi AA; Yaylim I; Ozkan NE; Zaman F; Halim TA; Chang HW
    Arch Immunol Ther Exp (Warsz); 2014 Dec; 62(6):459-74. PubMed ID: 25030086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
    Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
    Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX; Ong CN; Shen HM
    Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.